AZ has struggled to extend the label of Imfinzi beyond that in NSCLC, other than a 2022 approval for the drug in combination with its CTLA4 inhibitor Imjudo (tremelimumab) for patients with ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for ...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been recommended by the European Medicines Agency’s human medicines committee to treat an aggressive form of lung cancer. The Committee for Medicinal ...

At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab ... Last year, for example, the label for GSK’s PARP Zejula (niraparib) was narrowed to BRCA ...

AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.